Dr. Peter L. Anderson's lab focuses on improving HIV treatment methods through the development of personalized medication dosing strategies. The research aims to validate a system that allows patients to collect their own samples and test drug levels easily at home. This work is critical for optimizing long-acting antiretroviral therapies, ensuring that each patient's treatment is tailored to their unique needs, ultimately enhancing health outcomes for individuals living with HIV.

Dr. Linda Barlow's lab focuses on understanding how chemotherapy affects taste perception, especially regarding the cancer treatment drugs used for kidney cancer. The research explores how these drugs disrupt the regeneration of taste bud cells, particularly those responsible for sweet taste. The ultimate goal is to find ways to mitigate taste dysfunction in cancer patients, improving their quality of life during treatment.

Dr. Diana M. Cittelly's research focuses on understanding how hormone therapies and radiation can work together to treat aggressive breast cancers, particularly in young women who are at a higher risk of developing brain metastases. Her team studies the role of the hormone estradiol in promoting tumors and how treatments targeting this hormone might improve patient outcomes. By exploring how these therapies affect immune responses in the brain, her lab aims to develop more effective cancer treatments that could be translated from the lab to clinical practice.

Dr. Brice V McConnell's lab focuses on using sleep electroencephalography (EEG) to enhance our understanding of memory processing and brain health, specifically in the context of Alzheimer's disease. They aim to develop inexpensive digital biomarkers that can monitor cognitive health and detect early signs of neurodegeneration, which could significantly aid in diagnosing and managing Alzheimer's disease. By applying advanced signal processing and machine learning techniques, they analyze large datasets of sleep recordings to find patterns indicative of brain aging and cognitive decline.

Dr. James Christopher Costello's lab at the University of Colorado Denver focuses on understanding Down syndrome by examining how the genes on chromosome 21 influence various co-occurring health conditions. The lab uses innovative computational techniques, particularly in 'omics' data analysis, to find specific signals related to these diseases. Their work aims to improve care not only for individuals with Down syndrome but also for the broader community.

Dr. Angelo D'Alessandro's lab focuses on understanding how red blood cells age and respond to oxidative stress, which is crucial for oxygen transport in the human body. The lab investigates the process of ferroptosis, a unique form of cell death that occurs in response to iron-induced oxidative damage. By studying both in vivo and in vitro models, the research aims to uncover how this process affects red blood cell health and storage, with implications for blood transfusions and overall human health.

Dr. Jared Brown's lab at the University of Colorado Denver focuses on understanding how certain environmental exposures, particularly silica from burning agricultural crops, contribute to chronic kidney disease. His research also explores the role of mast cells in lung injury caused by chemical pollutants. By investigating these critical health issues, the lab aims to develop predictive models and potential treatments for diseases related to environmental toxins.

Dr. Tatiana G Kutateladze's lab studies how certain chemical changes in the molecular structure of DNA and proteins, known as epigenetic modifications, influence aging and diseases like Alzheimer's. Their research focuses on a specific modification on histones, the proteins that package DNA, and how this impacts gene expression and cellular function. By understanding these processes, the lab aims to find new ways to prevent or treat age-related disorders.

Dr. Christopher Peter Ford's lab focuses on understanding how dopamine signals contribute to movement and learning processes in the brain. By studying the mechanisms of dopamine transmission, the research aims to determine how these signals impact motor activities and their dysfunction in conditions like Parkinson's disease. The lab employs innovative methods to explore different dopamine release patterns and their effects on behavior, striving for insights that could lead to improved treatments for motor disorders.

Dr. Heide L. Ford's lab focuses on understanding the mechanisms behind aggressive pediatric cancers like Rhabdomyosarcoma (RMS) and Triple Negative Breast Cancer (TNBC). Their research aims to uncover how specific transcription factors influence tumor growth and differentiation, potentially leading to targeted therapies that minimize toxicity. By combining advanced genetic tools and animal models, the team seeks to develop better treatments for these challenging cancers.

Jed Noah Lampe's lab focuses on understanding the interactions between drugs and hormones, particularly in vulnerable populations like pregnant individuals. The lab conducts research to improve the safety of antiviral medications and to explore how pathogens, specifically the bacterium Pseudomonas aeruginosa, affect drug metabolism in patients with cystic fibrosis. By studying these interactions, the lab aims to prevent harmful side effects and develop better treatment strategies for infections and drug therapies.

Dr. John Bankston's lab at the University of Colorado Denver investigates ion channels, which are proteins that control ion flow in and out of cells. Specifically, the lab focuses on Acid-sensing ion channels (ASICs) and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, both of which are crucial for understanding cellular excitability, pain sensing, and heart function. Through their research, they aim to discover how lipids and other molecules influence these channels, with the potential to develop new therapeutic strategies.

Dr. Melanie S. Joy's lab at the University of Colorado Denver focuses on understanding how cancer immunotherapy, specifically immune checkpoint inhibitors (ICIs), can cause kidney damage. The research aims to develop preclinical models that simulate human conditions to study these kidney toxicities and identify ways to predict and detect these side effects early in cancer patients. The lab combines innovative animal models with clinical evaluations to bridge laboratory findings and patient care.

Dr. Breck A. Duerkop's lab focuses on understanding how bacteria exchange genetic material, which can lead to new traits like antibiotic resistance. Using a cutting-edge technique called transductomics, researchers in this lab analyze how viruses transfer genes among bacteria in the intestines, which is crucial for both microbial diversity and public health. The lab aims to identify these genetic exchanges in real-time to better understand their implications for human health and to develop therapies that can prevent the spread of harmful bacterial traits.

Dr. James V Degregori's research lab at the University of Colorado Denver focuses on how respiratory viral infections, such as influenza and SARS-CoV-2, affect dormant cancer cells in the lungs and lead to breast cancer metastasis. The lab investigates the connections between inflammation caused by these infections and the awakening of dormant cancer cells that can result in serious health complications. Their work aims to uncover mechanisms to prevent cancer recurrence and develop strategies for early detection and risk mitigation in cancer survivors.

Dr. Dmitri Simberg's lab focuses on developing innovative drug delivery systems using lipid nanoparticles for treating invasive glioblastoma, a highly aggressive brain tumor. The research aims to enhance the effectiveness of drug therapies by overcoming barriers in the brain and targeting tumor cells directly. By understanding the trafficking and formulation of lipid-based nanoparticles, the lab seeks to improve treatment outcomes for patients with this challenging disease.

Dr. Manisha N Patel's lab at the University Of Colorado Denver focuses on understanding how mitochondria, the energy powerhouses of cells, contribute to neuroinflammation and astrogliosis in epilepsy. By investigating the role of mitochondrial reactive oxygen species (mtROS) in neuronal-glial communication, the lab aims to identify potential new therapies for treating epilepsy. The research combines various techniques to explore how oxidative stress impacts brain function and inflammation in seizure models.

Dr. Sujatha Jagannathan's lab at the University of Colorado Denver focuses on understanding a muscle disease called facioscapulohumeral muscular dystrophy (FSHD). The lab's research investigates how a protein called DUX4 disrupts RNA processing in muscle cells, leading to toxicity and muscle degeneration. By uncovering the molecular mechanisms at play, the lab aims to identify potential new treatments for FSHD and other similar neuromuscular conditions.

Dr. Thomas Anchordoquy's research lab at the University of Colorado Denver focuses on improving cancer chemotherapy by developing strategies to minimize the off-target accumulation of drug-containing nanoparticles in healthy tissues. This innovative approach leverages the immune response to enhance drug delivery specifically to tumors while reducing adverse effects. The lab's work is essential in finding ways to make cancer treatments more effective and less toxic for patients.

Dr. James Roede's lab at the University of Colorado Denver focuses on understanding how environmental chemicals affect neurodevelopment, particularly in individuals with Down syndrome. They study specific cellular mechanisms that may lead to cognitive challenges in this population, exploring the role of toxic compounds and how they interact with genetic factors. The lab employs advanced techniques to investigate changes at the cellular and molecular levels that contribute to cognitive variability in Down syndrome.